Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has provided an announcement.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has received approval from the National Medical Products Administration for a new indication of its Class 1 innovative drug, Ivarmacitinib Sulfate Tablets, for the treatment of severe alopecia areata in adults. This approval marks a significant advancement for the company, potentially enhancing its market position and offering new treatment options for patients suffering from this chronic condition.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, focusing on the development and production of innovative drugs. The company operates in the pharmaceutical industry and is known for its research and development of new medications, particularly in the field of oncology and other therapeutic areas.
Average Trading Volume: 6,461,033
Current Market Cap: HK$374.9B
For detailed information about 1276 stock, go to TipRanks’ Stock Analysis page.